Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Botox reduces dysphagia in nonachalasia primary esophageal motility disorders

Botulinum toxin reduces dysphagia in patients with nonachalasia primary esophageal motility disorders, finds the most recent issue of Clinical Gastroenterology & Hepatology.

News image

Endoscopic injection of botulinum toxin has shown benefits for patients with diffuse esophageal spasm and nutcracker esophagus in small uncontrolled trials.

Dr Tim Vanuytsel from Belgium investigated the effect of botulinum toxin on symptoms of patients with diffuse esophageal spasm or nutcracker esophagus.

The team assessed manometry findings in a prospective, double-blind, randomized, controlled study.

The research team evaluated 22 patients with dysphagia-predominant, manometry-confirmed diffuse esophageal spasm or nutcracker esophagus at a tertiary care medical center.

50% of patients had a response 1 month after botulinum toxin injection
Clinical Gastroenterology and Hepatology

Patients were given injections of botulinum toxin or saline in 4 quadrants, at 2 and 7 cm above the esophagogastric junction.

After 1 month, patients crossed over between groups and received endoscopic injections of  botulinum toxin or saline.

When the study began and 4 weeks after each injection, the patients were assessed by esophageal manometry and completed a symptom questionnaire.

The doctors analyzed the responders that were defined based on modified Vantrappen criteria for achalasia.

After botulinum toxin injections, the team noted that patients had significant decreases in total symptom scores, this decrease was not observed in patients who received saline injections.

Moreover, botulinum toxin injection stabilized unintentional weight loss.

The researchers found that 50% of patients had a response 1 month after botulinum toxin injection, compared with 10% after saline injection.

The team observed that 30% of patients still had a response 1 year after botulinum toxin injection.

Botulinum toxin injection also caused a significant decrease in the mean esophagogastric junction pressure, compared with baseline.

Dr Vanuytsel's team concludes, "In a prospective controlled study of patients with diffuse esophageal spasm and nutcracker esophagus, injections of  botulinum toxin reduced symptoms and stabilized unintentional weight loss."

Clin Gastroenterol and Hepatol 2013: 11(9) 1115-1121
09 September 2013

Go to top of page Email this page Email this page to a colleague

 28 February 2015

Advanced search
 27 February 2015 
Obesity and weight-loss therapy
 27 February 2015 
MRE performance in staging liver fibrosis
 27 February 2015 
Bleeding in diverticulosis
 26 February 2015 
Familial colorectal cancer risk and primary cancer
 26 February 2015 
Questionnaires for GERD
 26 February 2015 
Herbal products and the liver
 25 February 2015 
Exercise and NAFLD
 25 February 2015 
IBD in Korea
 25 February 2015 
Immunosuppressive therapy and T. whipplei
 24 February 2015 
Clinical trials in pediatric IBD
 24 February 2015 
Reducing health care costs in IBD
 24 February 2015 
GI bleeding after anticoagulation interruption
 23 February 2015 
Visceral abdominal obesity and IBS
 23 February 2015 
Crohn's outcomes with infliximab
 23 February 2015 
Intestinal microbiota and celiac disease
 20 February 2015 
H. pylori eradication
 20 February 2015 
Antiviral treatment and Hep C outcomes
 20 February 2015 
C. diff testing in IBD
 19 February 2015 
Intestinal microbiota in IBS
 19 February 2015 
Peptic ulcer bleeding mortality in liver disease
 19 February 2015 
Fecal microbial transplant in active Crohn's disease
 18 February 2015 
Genetic testing and GI cancers
 18 February 2015 
Placebo analgesia in functional abdominal pain
 18 February 2015 
Successful Hep C virus therapy
 17 February 2015 
Quality measures and colonoscopist selection
 17 February 2015 
Global incidence of esophageal cancer
 17 February 2015 
Anti-viral treatment and survival in Hep C
 16 February 2015 
Saliva for the diagnosis of GERD
 16 February 2015 
H pylori eradication therapy
 16 February 2015 
Medical marijuana for digestive disorders
 13 February 2015 
Beta-blockers in cirrhosis
 13 February 2015 
Liver disease and peptic ulcer bleeding
 13 February 2015 
Prevalence of microscopic colitis
 12 February 2015 
Liver disease in chronic Hep C
 12 February 2015 
Patient-reported outcomes in Hep C
 12 February 2015 
Patientsí colonoscopist selection
 11 February 2015 
NAFLD and CVD
 11 February 2015 
Guidelines for the diagnosis of hepatocellular carcinoma
 11 February 2015 
Hepatic decompensation in Hep C cirrhosis
 10 February 2015 
Percutaneous endoscopic gastrostomy
 10 February 2015 
Factors that influence hepatic steatosis
 10 February 2015 
Gene variants and Crohn's susceptibility
 09 February 2015 
Factors that influence gallstone surgery
 09 February 2015 
Factors associated with increased mortality in cirrhosis
 09 February 2015 
Use of immunomodulators in IBD
 06 February 2015 
Colorectal cancer risk in IBD
 06 February 2015 
H. pylori and peptic ulcer bleeding
 06 February 2015 
IBS and somatization
 05 February 2015 
GERD, dyspepsia and IBS symptoms
 05 February 2015 
Quality of life in Crohn's after antitumor necrosis factor agents
 05 February 2015 
Thalidomide and refractory Crohn's
 04 February 2015 
Telemedicine in IBD
 04 February 2015 
Infliximab and muscle wasting in Crohn's
 04 February 2015 
Resistance mutations in chronic Hep B
 03 February 2015 
Testosterone in advanced liver disease
 03 February 2015 
Mortality in peptic ulcer bleeding
 03 February 2015 
Colonoscopic remission of ulcerative colitis
 02 February 2015 
Colonoscopy and colon cancer risk in IBD
 02 February 2015 
Sirolimus in Hep C virus infected liver graft recipients
 02 February 2015 
Treatment of C. diff in adults

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us